samplefor weight loss
99%+ · 5mg · Lyophilized
Bulk discount
3+ pcs
€56.05
−5%
5+ pcs
€53.10
−10%
10+ pcs
€50.15
−15%
Discount is applied automatically at checkout.
🎉 One free — saved €59
Preview: offer goes live at launch.
The catalog is not yet accepting orders. Join the list.
In Stock - Ships within 24 hours
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
Retatrutide
Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes
In short
Triple agonist of GLP-1, GIP, and glucagon receptors studied in clinical models for complex metabolic regulation.
Best sellers
Education
Related resources
Ready-to-use starter kit
Retatrutide is a synthetic peptide currently undergoing Phase 3 clinical trials by Eli Lilly (the TRIUMPH series). At the molecular level, it functions as a triple agonist, simultaneously activating the GLP-1, GIP, and glucagon receptors. Scientists are studying this compound in in vitro environments and animal models to observe its cellular interactions. This molecule lacks regulatory approval from the EMA or in Bulgaria and is offered strictly as a research-grade product for laboratory work, not as a medical drug.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
Retatrutide (LY3437943) is a novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase III TRIUMPH-4 trial (Dec 2025) achieved 28.7% weight loss (71.2 lbs) at 68 weeks with 12mg dose - the highest recorded for any obesity medication. Currently in late-stage Phase III development by Eli Lilly with FDA approval expected 2026-2027.
24.2% weight loss (TRIUMPH-1, NEJM 2023) - record for non-bariatric First triple agonist GLP-1+GIP+glucagon UCP1 thermogenic activation HbA1c -1.6-2.2%
Activates GLP-1 for appetite suppression, GIP for insulin sensitivity, and glucagon for increased energy expenditure and hepatic fat oxidation
Clinical trials demonstrate 17.5% at 24 weeks and 24.2% at 48 weeks - highest recorded for any obesity medication in development
Continuous weight loss throughout trials with no plateau reached at 48 weeks, suggesting greater long-term potential than current therapies
Addresses obesity through appetite suppression, increased energy expenditure, and improved metabolic efficiency via three hormone pathways
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
Any time of day, maintain same day each week for consistency
[Calculator]
Change water and dose · results update in real time
from product
Visual indicator
Pull to mark 10
10marks
Standard insulin syringe 1 ml (100 marks)
Concentration
2.50mg/ml
Dose volume
0.100ml
U-100 units
10units
Doses per vial
20doses
Recommended needle
29G–30G / 1 ml insulin
Small volume — draw slowly; 30G works for finer precision
Cycle planner: vials for 12 weeks, cost, schedule
Opens full calculator
Results are reference values - for in vitro work. Verify against the published literature for the specific peptide.
[Step by step]
6 steps from a sealed vial to the injection. Plain language.
Peptide vial (5 mg), bacteriostatic water vial, 1 larger syringe (3-5 ml) for drawing water and 1 insulin (1 ml) for doses. Alcohol swabs for sanitizing the caps.
Wash your hands before starting.
Wipe the rubber cap of the water vial with an alcohol swab. Insert the needle, invert the vial and draw exactly 2 ml. Get the exact volume from the calculator.
Larger syringe = smaller error in volume.
Wipe the peptide vial cap. Tilt the vial 45° and release the water SLOWLY down the inner wall. Peptides are fragile — a direct stream onto the powder denatures them.
SLOWLY · DOWN THE WALL · NOT ONTO THE POWDER.
Hold the vial between both palms and swirl slowly. DO NOT shake or flip sharply — peptides break down under mechanical stress.
DON'T SHAKE. Like tea — not like a cocktail.
The powder should fully dissolve. The solution is clear, no visible particles. If cloudy or with sediment — discard (wrong water or bad batch).
Clear = OK. Cloudy = discard.
With the insulin syringe draw the exact marks from the calculator. Swab the skin (abdomen 5 cm around the navel, thigh, or buttock), pinch a fold, insert at 45-90° and inject slowly.
Rotate sites every injection to avoid lipohypertrophy.
Schedule
Any time of day, maintain same day each week for consistency
Remove Retatrutide vial from refrigeration and allow to reach room temperature (15-20 minutes)
Clean vial top with alcohol swab and allow to air dry completely
Add calculated amount of bacteriostatic water slowly down the side of the vial to minimize foaming
Gently swirl the vial in circular motions - DO NOT shake vigorously as this may damage the peptide structure
Allow to fully dissolve (may take 2-3 minutes) - solution should be clear and colorless
Store reconstituted solution in refrigerator (2-8°C) and use within 28 days
Draw calculated dose using insulin syringe, inject subcutaneously into abdomen, thigh, or upper arm
Rotate injection sites weekly to prevent lipodystrophy and maintain absorption consistency
Nausea
common·Phase 2 NEJM 2023
Diarrhea
common
Vomiting
common
Transient heart rate increase (5-7 bpm)
common·Phase 2
Constipation
common
Compatibility
The pairings below come from research literature and established biohacker stacking patterns. Click a card for the full reasoning - when the partner is in our catalog you'll see a direct order link too.
This is a literature overview, not medical advice. Pairs not listed are not proven safe - they simply lack enough published data.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Phase III TRIUMPH-4 Trial - Eli Lilly (Dec 2025)
Human | 9-12mg weekly | 68 weeks | 28.7% weight loss (71.2 lbs)
First successful Phase III trial in 445 adults with obesity and knee osteoarthritis. 12mg dose achieved 28.7% weight loss (71.2 lbs from 248.5 lb baseline) with 75.8% pain reduction. Discontinuation rates 12-18% due to GI effects; new dysesthesia signal in 8.8-20.9% of participants.
View the studyMASLD Substudy - Nature Medicine (2024)
Human | 8-12mg weekly | 24 weeks | 82% liver fat reduction
Metabolic dysfunction-associated steatotic liver disease study showing dramatic liver fat reductions with normalization in over 90% of participants at highest doses.
View the studyTRIUMPH-Outcomes Cardiovascular Study (2024-2029)
Human | 8mg weekly | 248 weeks | 10,000 participants with ASCVD
Major cardiovascular outcomes trial assessing effects on MACE and kidney outcomes in participants with obesity and established cardiovascular or kidney disease.
View the studyPhase II Obesity Trial - NEJM (2023)
Human | 1-12mg weekly | 48 weeks | 24.2% mean weight reduction
Landmark randomized controlled trial in 338 participants with obesity showing dose-dependent weight loss with 12mg achieving 24.2% reduction - the highest weight loss recorded for any obesity medication in clinical trials at the time.
View the studyPhase II Type 2 Diabetes Study - Lancet (2023)
Human | 0.5-12mg weekly | 36 weeks | 16.9% weight loss, -2.02% HbA1c
Trial in 281 participants with type 2 diabetes demonstrating significant glycemic control improvements with HbA1c reductions up to 2.16% and concurrent substantial weight loss.
View the studyTRIUMPH-1 Phase III Trial (2023-2026)
Human | 4-12mg weekly | 72 weeks | Obesity without comorbidities
Pivotal Phase III trial in participants with obesity without diabetes or osteoarthritis, evaluating maintenance dose (4mg) in addition to 9mg and 12mg. Results expected 2026.
View the studyPhase I Pharmacokinetics - Cell Metabolism (2022)
Human | Single ascending dose | 12 weeks | Established 6-day half-life
First-in-human study establishing safety profile, dose-proportional pharmacokinetics, and the extended half-life enabling once-weekly administration.
View the study
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
